Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BMY

Do Wall Street Analysts Like Bristol-Myers Squibb Stock?

Although Bristol-Myers Squibb has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Bristol-Myers Squibb Earnings Preview: What to Expect

Bristol-Myers Squibb is approaching its first-quarter earnings release this month, and Wall Street is forecasting a double-digit percentage fall in earnings.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Retreat as Tech Stocks Fall and the US Labor Market Weakens

The S&P 500 Index ($SPX ) (SPY ) today is down -1.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.49%. March E-mini S&P futures (ESH26 ) are down -1.29%, and March E-mini Nasdaq futures...

Barchart

Bristol-Myers Squibb Stock Outlook: Is Wall Street Bullish or Bearish?

Bristol-Myers Squibb has lagged the broader market over the past year, but analysts are growing optimistic about the company’s outlook.

Barchart

2 Buffett Stocks to Load Up On—And 1 to Ditch

With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.

MarketBeat

What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline in the company’s bottom-line figure.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The Healthcare Sector is Gaining Momentum. Watch This Stock Chart for a Reversal Setup.

Our top chart strategist is tracking a 3-candle drop pattern on AHR.

Barchart

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Bristol Myers Squibb Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.

Benzinga

Is Bristol-Myers Stock Underperforming the S&P 500?

Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

Barchart

Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.

Benzinga

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

Bristol Myers Squibb Co. (NYSE:BMY), in collaboration with Johnson Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS)…

Benzinga

Two Straddles Define Wednesday’s Unusual Options Activity Across Key Stocks

Among Wednesday’s 35 most unusually active options, two emerged as notable straddle setups appealing to both bullish and bearish traders. These potential plays revolve around some of the market’s most familiar and widely followed stocks.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

The Saturday Spread: Using the ‘Taxonomical’ Approach to Extract Profits

While fundamental and technical analyses dominate the finance ecosystem, there’s another, more powerful mechanism to succeed in the markets.

Barchart

What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report

Bristol-Myers Squibb is set to release its third-quarter results by the end of this month, and analysts expect a notable double-digit drop in earnings.

Benzinga

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Benzinga

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co (NYSE:BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

Barchart

How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?

Bristol-Myers Squibb has notably underperformed the broader pharma space over the past year, and analysts have turned cautious on the stock’s prospects.

Benzinga

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

Bristol Myers Squibb Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year.

Barchart

Is Wall Street Bullish or Bearish on Bristol-Myers Stock?

While Bristol-Myers Squibb has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Benzinga

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial

Bristol Myers Squibb Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions.

Benzinga

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.